Latest Bids From Kuwait

description: Dynamic Procurement System for the Hiring of Audiovisual Production Services
Closing date: 2026-10-04
Tender base budget: Euros
Type of Contract: Services
Codigo CPV: 92110000 Film production services cinema and video tapes and related services.

Development works on the Ngatt-Febadi-Likok road section Project name: Phase II of the Batchenga-Ntui-Yoko-Lena-Tibati-Ngaoundére road improvement project: Ngatt-Febadi-Likok section

Technical assistance to develop the legal and regulatory framework of the Sukuk in Algeria and support the Ministry of Finance in the launch of the first program of Sukuk Sovereign - GPN

Comprehensive Technical Assistance for Equipment and Devices in Restricted Areas.

MogMT No. 607/24-EA "Consumables, devices and products for cardiac surgical medical needs"

description: Contracting of the Works of "Buildings", "Public Roads, Parks and Gardens" and "Facilities", of an Amount Less than 200,000 Euros, for the Illustrious City Council of Molina De Segura, Within the Framework of
Closing date: 2028 -09-25
Tender base budget: Euros
Contract type: Works

To Obtain A Copy Of The Notice Of Funding Opportunity (Nofo) Please Go To The Arpa-E Website At Https://Arpa-E-Foa.Energy.Gov.To Apply To This Nofo, Applicants Must Register With And Submit Application Materials Through Arpa-E Exchange (Https://Arpa-E-Foa.Energy.Gov/Registration.Aspx).For Detailed Guidance On Using Arpa-E Exchange, Please Refer To The Arpa-E Exchange User Guide (Https://Arpa-E-Foa.Energy.Gov/Manuals.Aspx).Arpa-E Will Not Review Or Consider Concept Papers Submitted Through Other Means. For Problems With Arpa-E Exchange, Email Exchangehelp@Hq.Doe.Gov (With Nofo Name And Number In The Subject Line). Questions About This Nofo? Check The Frequently Asked Questions Available At Http://Arpa-E.Energy.Gov/Faq.For Questions That Have Not Already Been Answered, Email Arpa-E-Co@Hq.Doe.Gov. Agency Overview The Advanced Research Projects Agency - Energy (Arpa-E), An Organization Within The Department Of Energy (Doe), Is Chartered By Congress In The America Competes Act Of 2007 (P.L. 110-69), As Amended By The America Competes Reauthorization Act Of 2010 (P.L. 111-358), As Further Amended By The Energy Act Of 2020 (P.L. 116-260): “(A) To Enhance The Economic And Energy Security Of The United States Through The Development Of Energy Technologies That— (I) Reduce Imports Of Energy From Foreign Sources; (Ii) Reduce Energy-Related Emissions, Including Greenhouse Gases; (Iii) Improve The Energy Efficiency Of All Economic Sectors; (Iv) Provide Transformative Solutions To Improve...

The Purpose Of This Notice Of Funding Opportunity (Nofo) Is To Support Rigorous Analytical Validation Of Method(S) Used For Measuring Biomarkers For Neurological And Neuromuscular Disorders For Use In Clinical Trials Or Clinical Practice. Applicants Must Justify The Unmet Need For The Biomarker(S) And Measurement Methods And Specify One Or Two Context(S) Of Use For The Biomarker(S). Activities Supported Include Optimizing And Evaluating The Accuracy, Precision, Reportable Range, And Analytical Sensitivity And Specificity Of The Detection Method Across Multiple Sites And Operators And Establishing Reference Intervals And Quality Control Procedures. Multi-Site Applications Are Expected But Not Required.

The Nih Research Education Program (R25) Supports Research Education Activities In The Mission Areas Of The Nih. The Overarching Goal Of This R25 Program Is To Support Educational Activities That Help Recruit Individuals With Specific Specialty Or Disciplinary Backgrounds To Research Careers In Biomedical, Behavioral And Clinical Sciences.

The Purpose Of This Program Announcement (Par) Is To Enable Clinical Validation Of Strong Candidate Biomarkers For Neurological Diseases And Conditions. Specifically, The Goal Of This Par Is To Enable The Rigorous Validation Of Biomarker Measurements Within The Clinical Population Of Interest To Establish The Positive And Negative Predictive Values Of The Candidate Biomarker Consistent With Fda Guidelines. This Par Assumes That 1) A Candidate Biomarker Has Already Been Identified, 2) Detection Method Technology Has Already Been Developed And Analytically Validated, And 3) The Research And/Or Clinical Need And Potential Context Of Use Has Been Identified.